MINUTES OF THE 47TH CLINICAL STUDIES COMMITTEE MEETING (SUMMARY)

Pharmacy Services Division, Drug Regulatory Authority of Pakistan

File No: 16-47/2023-CSC (PS)

DECEMBER 22, 2023
DRUG REGULATORY AUTHORITY OF PAKISTAN
Prime Minister Health Complex, Park Road, Chak Shahzad,
Islamabad.

12.	**ITEM XII:** IRB APPROVAL FOR MAYO HOSPITAL LAHORE FOR INVESTIGATOR BROCHURE VERSION 3.0 DATED MARCH 13, 2023, PROTOCOL AMENDMENT VERSION 4.0 OF JUNE 6, 2023 AND ICF AMENDMENT V3.0 PAK DATED AUGUST 08,2023 FOR TRIAL "A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF THE EFFICAY AND SAFETY OF BCD-201 (JS BIOCAD) AND KEYTRUDA IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. **F. NO.03-24/2023 DD (PS).**	31-34
13.	**ITEM XIII:** CLOSEOUT REPORT QUERY RESPONSE FROM SHIFA INTERNATIONAL HOSPITAL FOR CLINICAL TRIAL "A RANDOMIZED, PHASE-III PLACEBO CONTROLLED TRIAL OF COLCHICINE FOR THE PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY (COP-AF)" CT-0013 / **03-37/2020-CT**	34-36
14.	**ITEM XIV:** CLOSEOUT REPORT QUERY RESPONSE FROM SITE OF SHIFA INTERNATIONAL HOSPITAL DATED 10.10.2023 OF THE CLINICAL TRIAL "PERI-OPERATIVE ISCHEMIC EVALUATION-3 (POISE-3) TRIAL. **F.NO.03-07/2019-CT(PS)**	36-38
15.	**ITEM XV:** ADDITION OF MISSING DOCUMENTS IN AMENDMENTS APPROVAL FOR CLINICAL TRIAL "A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVAUATE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR IN HIGH RISK OUTPATIENTS WITH COVID-19. **F.NO.03-37/2023-DD-CT(PS)**	39-40
16.	**ITEM XVI:** APPLICATION FOR APPROVAL OF A PHASE-III CLINICAL TRIAL TITLED "A DOUBLE-BLIND, RANDOMIZED CLINICAL STUDY OF THE EFFICACY AND SAFETY OF MONOTHERAPY WITH BCD-254 AND **DARZALEX®** IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA" FROM SHAHEED ZULFIQAR ALI BHUTTO MEDICAL UNIVERSITY, ISLAMABAD. **F. No.03-49/2023-CT (PS).**	40-45
17.	**ITEM XVII:** APPLICATION FOR AMENDMENT IN ALREADY APPROVED CLINICAL TRIAL TITLED "TRANSNASAL CAPSULE **ENDOMICROSCOPY** FOR VISUALIZATION OF THE SMALL INTESTINE IN ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) POPULATION IN PAKISTAN. **F. No.03-18/2020-DD (PS).**	45-49
18.	**ITEM XVIII: (Amendments, Extension in Trial Duration & Progress Report)** **Case-I (Amendments)** MISCELANNEOUS APPLICATIONS RELATED TO CLINICAL TRIAL TITLED "A RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVT06 COMPARED WITH EU-EYLEA ® IN SUBJECTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION **(ALVOEYE)**", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-12/2022-CT.** **Case-II (Extension in Trial Duration & Progress Report)** MISCELANNEOUS APPLICATIONS RELATED TO CLINICAL TRIAL TITLED "A RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVT06 COMPARED WITH EU-EYLEA ® IN SUBJECTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION **(ALVOEYE)**", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-12/2022-CT.**	49-54
19.	**ITEM XIX: (Addition of CTS in already approved Clinical Trial)** APPLICATION FOR ADDITIONAL CTS TO BE INCLUDED IN ALREADY APPROVED CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL PHASE IIB STUDY TO ASSESS EFFICACY AND SAFETY OF HH-003 INJECTION IN SUBJECTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION **(HH-003-204)**", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-45/2023-CT (PS)**	54-55
20.	**ITEM XX: (Amendments in documents and increase in 15 subjects)** APPLICATION FOR AMENDMENTS IN DOCUMENTS AND INCREASE IN 15 SUBJECTS IN ALREADY APPROVED CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL PHASE IIB STUDY TO ASSESS EFFICACY AND SAFETY OF HH-003 INJECTION IN SUBJECTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION **(HH-003-204)**", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI**. F. No.03-45/2023-CT (PS)**	55-59
21.	**ITEM XXI: (Amendment)**	59-60

	APPLICATION FOR AMENDMENT IN ALREADY APPROVED CLINICAL TRIAL TITLED "A PHASE 3, RANDOMIZED, OBSERVER-BLIND, CONTROLLED, MULTICENTER, CLINICAL STUDY TO EVALUATE IMMUNOGENICITY AND SAFETY OF A HIGH-DOSE MF59 ADJUVANTED QUADRIVALENT SUBUNIT CELL-DERIVED INFLUENZA VACCINE (aQIVc HD) IN COMPARISON WITH A NON-ADJUVANTED QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (QIVr) AND AN MF59-ADJUVANTED QUADRIVALENT SUBUNIT EGG-DERIVED INFLUENZA VACCINE **(aQIV)**, IN ADULTS AGED 50 YEARS AND OLDER", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **(Seqirus-II) F. No.03-46/2023-CT (PS)**	
22.	**ITEM XXII: (Amendment, Progress Report and Global SUSAR Report)** **Case-I: Amendments** APPLICATION/NOTIFICATION FOR NON-SUBSTANTIAL AMENDMENT FOR APPROVAL OF CLINICAL TRIAL TITLED "A PHASE-III, MULTICENTRE. RANDOMIZED, DOUBLE-BLIND, 24-WEEK STUDY OF THE CLINICAL AND ANTIVIRAL EFFECT OF S-217622 COMPARED WITH PLACEBO IN NON-HOSPITALIZED PAI1ICIPANTS WITH COVID-19", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-25/2023-CT (PS)** **Case-II:** PROGRESS REPORT AND GLOBAL SUSAR REPORT OF CLINICAL TRIAL TITLED "A PHASE-III, MULTICENTRE. RANDOMIZED, DOUBLE-BLIND, 24-WEEK STUDY OF THE CLINICAL AND ANTIVIRAL EFFECT OF S-217622 COMPARED WITH PLACEBO IN NON-HOSPITALIZED PAI1ICIPANTS WITH COVID-19", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-25/2023-CT (PS)**	60-69
23.	**ITEM XXIII: (Extension in Trial Duration & Progress Reports)** APPROVAL FOR SCYNEXIS PROTOCOL NUMBER SCY-078-305, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SCY-078-305 **(IBREXAFUNGERP)** IN PATIENTS WITH FUNGAL DISEASES THAT ARE REFRACTORY TO OR INTOLERANT OF STANDARD ANTIFUNGAL TREATMENT **(FURI). F.No.03-61/2021-CT**	70-71
24.	**ITEM XXIV: (Extension in Trial Duration)** APPROVAL FOR SCYNEXIS PROTOCOL NUMBER SCY-078-305, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SCY 078 **(IBREXAFUNGERP)** IN PATIENTS WITH CANDIDIASIS INCLUDING CANDIDEMIA, CAUSED BY CANDIDA AURIS **(CARES)**. **F.No.03-15/2021-CT**	71
25.	**ITEM XXV:** APPLICATION FOR IMPORT OF ADDITIONAL QUANTITIES OF IMPs FOR ALREADY APPROVED PHASE-IV CLINICAL TRIAL TITLED, "RANDOMIZED, OPEN LABEL, MULTICENTER, NON-INFERIORITY CLINICAL TRIAL FOR NEW TREATMENT MODALITIES FOR CUTANEOUS LEISHMANIASIS CAUSED BY **LEISHMANIA TROPICA**". **F. No.03-60/2021-DD (PS).**	71-73
26.	**ITEM XXVI: (Ratification of Typo Error)** APPLICATION FOR EXTENSION IN TRIAL DURATION AND AMENDMENT IN PROTOCOL AND RELATED DOCUMENTS OF ALREADY APPROVED PHASE-IV CLINICAL TRIAL TITLED, "RANDOMIZED, OPEN LABEL, MULTICENTER, NON-INFERIORITY CLINICAL TRIAL FOR NEW TREATMENT MODALITIES FOR CUTANEOUS LEISHMANIASIS CAUSED BY **LEISHMANIA TROPICA**". **F. No.03-60/2021-DD (PS).**	73-74
27.	**ITEM XXVII: Close-Out Report** CLINICAL TRIAL "PREVENTION OF METRNAL & NEONATAL DEATH/INFECTIONS WITH A SINGLE ORAL DOSE OF AZITHROMYCIN IN WOMEN IN LABOR (IN LOW & MIDDLE-INCOME COUNTRIES), A RANDOMIZED CONTROLLED TRIAL. **(A-PLUS). F. No.03-09/2019-DD (PS)**	74-75
28.	**ITEM XXVIII: (Detailed Progress Report & END of Treatment Notification)** **Case-I: (Detailed Progress Report)** DETAILED PROGRESS REPORT OF CLINICAL TRIAL TITLED "A PHASE-III, RANDOMIZED, OBSERVER-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF SEQIRUS-CELL-BASED QUADRIVALENT SUBUNIT INFLUENZA VIRUS VACCINE **(QIVc)** COMPARED TO A NON-INFLUENZA VACCINE WHEN ADMINISTERED IN HEALTHY SUBJECTS AGED 6 MONTHS THROUGH 47 MONTHS", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **(Seqirus-I) F. No.03-11/2022-CT (PS)** **Case-II: (END of Treatment Notification)**	75-82

	END OF TREATMENT NOTIFICATION OF CLINICAL TRIAL TITLED "A PHASE-III, RANDOMIZED, OBSERVER-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF SEQIRUS-CELL-BASED QUADRIVALENT SUBUNIT INFLUENZA VIRUS VACCINE **(QIVc)** COMPARED TO A NON-INFLUENZA VACCINE WHEN ADMINISTERED IN HEALTHY SUBJECTS AGED 6 MONTHS THROUGH 47 MONTHS", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **(Seqirus-I) F. No.03-11/2022-CT (PS)**	
29.	**ITEM XXIX: (Clinical Study Report)** CLINICAL STUDY REPORT OF CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFICACY & SAFETY OF **CBP-307** IN SUBJECTS WITH MODERATE TO SEVERE **ULCERATIVE COLITIS (UC)**". **F.NO.03-59/2021 DD (PS).**	82-84
30.	**ITEM XXX: (SAE & Study Progress Reports)** SAE AND STUDY PROGRESS REPORTS OF CLINICAL TRIAL TITLED "EFFECTIVENESS OF NOVEL APPROACHES TO RADICAL CURE WITH TAFENOQUINE AND PRIMAQUINE **(EFFORT)**- A RANDOMIZED CONTROLLED TRIAL IN P. VIVAX PATIENTS". FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **F. No.03-10/2022-DD (PS)**	84-86
31.	**ITEM XXXI: (Update for 1st DSMB for Pakistan.)** APPLICATION FOR APPROVAL OF CLINICAL TRIAL TITLED "A MULTI-COUNTRY, MULTI-CENTER, OPEN-LABELLED, RANDOMIZED, CONTROLLED, EXTENDED PHASE III CLINICAL TRIAL TO EVALUATE THE IMMUNOGENICITY AND TOLERABILITY OF SABIN STRAIN INACTIVATED POLIOVIRUS VACCINE ADMINISTERED WITH OR WITHOUT ROUTINE INFANT VACCINES", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. **(sIPV) F. No.03-40/2023-CT (PS).**	86-87
32.	**ITEM XXXII: (DSUR & Clinical Study Report)** DSUR AND CLINICAL STUDY REPORT (CSR) OF FOR CLINICAL TRIAL TITLED "A MULTICENTER, SEAMLESS, RANDOMIZED, THIRD-PARTY-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY & EFFICACY OF MEPLAZUMAB (INJECTION) IN ADDITION TO STANDARD CARE FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS" **F.NO.03-54/2021 DD (PS).**	88-89
33.	**ITEM XXXIII:** REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF **PERISPA (EPERISONE)** 50 MG TABLETS MANUFACTURED BY M/S PLATINUM PHARMACEUTICALS (PVT) LIMITED, KARACHI. COMPARED WITH MYONAL (EPERISONE) 50MG TABLETS MANUFACTURED BY M/S EISAI Co. LTD., JAPAN. **F. No. 14-02/2022 DD (PS)**	90-93
34.	**ITEM XXXIV:** BIO EQUIVALENCE STUDY OF **EMPA-Q** 25MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.	94-97
35.	**ITEM XXXV:** BIO EQUIVALENCE STUDY OF **QAZZO** 20MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.	97-100
36.	**ITEM XXXVI:** BIO EQUIVALENCE STUDY OF **RIVA Q** 20MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.	101-104
37.	**ITEM XXXVII:** BIO EQUIVALENCE STUDY OF **ZUNE** 40MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.	104-107
38.	**ITEM XXXVIII:** REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF **AZITMA®** (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH ZITHROMAX® (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S PFIZER PAKISTAN. **F. No. 14-06/2020 DD (PS).**	108-110
39.	**ITEM XXXIX:** REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF **DELANZO™ DR** 60MG (DEXLANSOPRAOLE) CAPSULE OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH DEXILANT® 60MG (DEXLANSOPRAOLE) CAPSULE**. F. No. 14-02/2020 DD (PS)**	110-112

The 47th meeting of the Clinical Studies Committee was held on 22nd December, 2023 in the Committee Room, Drug Regulatory Authority of Pakistan, T.F. Complex, G-9/4, Islamabad. The meeting was chaired by Dr. Obaidullah, Director Pharmacy Services. The meeting was started with recitation of the Holy Verses of Quran.

2. The meeting was attended in-person by the following members: -

Sr. No.	Name	Designation	
i.	Dr. Obaidullah	Director Pharmacy Services Division.	*Ex-officio Chairman*
ii.	Prof. Dr. Fazal Subhan	Department of Pharmacy, CECOS University of IT and Emerging Sciences, Peshawar, Khyber Pakhtunkhwa.	Member
iii.	Dr. Faiza Bashir	Nominee of Chairman, Pakistan Health Research Council, Islamabad.	Member
iv.	Dr. Mirza Tasawer Baig	Associate Professor, Department of Pharmacy Practice, Faculty of Pharmacy, Ziauddin University, Karachi and Clinical Pharmacist at Dr. Ziauddin Hospital, Karachi, Sindh.	Member
v.	Ahsan Ul Haq Athar	Deputy Director, Pharmacy Services Division.	*Ex-officio Secretary*

3. Following members attended the meeting online through Team software.

i.	Prof. Dr. Saeed Ahmad Khan	Professor of Medicine Bolan Medical College Quetta presently serving as head of Medicine Department Jhalawan Medical College Khuzdar, Balochistan.	Member
ii.	Mr. Waqas Latif	Data Analyst/Biostatistician in Quality Enhancement Cell (QEC) at University of Health Sciences, Lahore, Punjab.	Member

4. Mr. Malik Muhammad Asad, Mr. Nouman Yousuf, Mr. Hafiz Muhammad Jawad Ali and Mr. Shafqat Hussain Danish assisted the Committee and Secretary in presentation of the agenda.

AGENDA ITEM I:

CONFIRMATION OF THE MINUTES OF THE 46th CLINICAL STUDIES COMMITTEE MEETING.

The minutes of the 46th CSC meeting held on 27th October, 2023. Minutes were shared with CSC members through email/ WhatsApp group on 01st November 2023. The CSC members submitted their consent and no comments/queries were received from the members. Accordingly, after approval of the minutes, decisions taken in the meeting have been communicated to all applicants and are placed for confirmation by members.

2. Submitted for confirmation of CSC Members.

Decision:

All the Members of the CSC confirmed the Minutes of 46th CSC meetings.

AGENDA ITEM II:

APPLICATION FOR LICENSE TO ACT AS CLINICAL TRIAL SITE FROM INSTITUTE OF CHEST DISEASE, KOTRI F. No.15-50/2020- DD (PS).

Decision:

The CSC after detailed deliberation decided to grant the renewal of license (CT 0036) for three years (w.e.f. 24th August 2023) to act as clinical trial site for Phase III (end-TB-Q trial) to CTS situated at Institute of Chest Diseases, Kotri.

AGENDA ITEM III:

APPLICATION FOR LICENSE TO ACT AS TRIAL SPECIFIC NON-INFERIORITY TRIAL FOR CUTANEOUS LEISHMANIASIS (PHASE-IV) CLINICAL TRIAL SITE FROM BOLAN MEDICAL COMPLEX IN QUETTA F. No.15-36/2023-CTS.

Decision:

The CSC discussed the inspection report and verified the storage conditions of Investigational Medicinal Product (Miltefosine Capsules), i.e., room temperature. Hence, the Committee decided to grant the license to act as Clinical Trial Site for Phase-IV clinical trial titled "Randomized, open label, multicenter non-inferiority clinical trial for new treatment modalities for cutaneous leishmaniosis caused by Leishmania tropica" to Bolan Medical Complex Hospital, Quetta.

AGENDA ITEM IV:

APPLICATION FOR LICENSE TO ACT AS TRIAL SPECIFIC NON-INFERIORITY TRIAL FOR CUTANEOUS LEISHMANIASIS (PHASE-IV) CLINICAL TRIAL SITE FROM GOVERNMENT NASSER ULLAH KHAN BABAR MEMORIAL HOSPITAL, PESHAWER F. No.15-35/2023 DD-CTS.

Decision:

The CSC after detailed deliberation decided to defer the case for reasons already communicated to the applicant with advise to re-inspect the facility after submission of the compliance report fulfilment of following shortcomings:

i. The process for administration of ICF needs to be improved in accordance with the ICH GCP guidelines ensuring the availability of qualified person and dedicated space /facility

ii Dedicated pharmacy for storage and dispensing of IMP along with research pharmacist to be established complying with good storage practices is required

iii. Data archiving facilities with the control access and retrievability is required to be established
iv. Data handling and security and infrastructure IT related needs to be prepared and implemented
v. Research nursing staff equipped with IPC and GCP training is required along with SOPs for infectious waste disposal
vi. Emergency evacuation plan and patient transfer protocol in case of SAEs needs to be formulated and implemented"

AGENDA ITEM V:

APPLICATION FOR TRIAL SPECIFIC (MRI-MNK01-301) LICENSE TO ACT AS CLINICAL TRIAL SITE (REFERRAL) FROM THE NATIONAL INSTITUTE OF CHILD HEALTH, KARACHI F. No.15-44/2023 CTS.

Decision:

The CSC after detailed deliberation decided to defer the request of National Institute of Child Health (NICH), Rafique (H.J.) Shaheed Road, Karachi, to act as Referral Clinical Trial Site for Clinical Trial "A phase III, randomized, double blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum B. infantis) supplementation versus placebo on weight gain in underweight infant" due to following reasons: -

i. The Clinical Trial "A phase III, randomized, double blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum B. infantis) supplementation versus placebo on weight gain in underweight infant" is already holded / stopped due to reported SAEs and communicated to PI and site Investigators vide letter No.03-31/2023-dd-PS, dated…08th December 2023

ii. For the fulfilment/ clarification of following shortcomings/ queries;

a. Relevant provision of Bio-Study Rules under which Referral site can be licensed only as referral site
b. Layout plan of hospital is attached while layout plan of Clinical Trial Site (CTS) required.
c. Machinery and Equipment present in hospital attached while details of Machinery/ equipment of clinical trial site required.
d. CVs of Dr. Farah Qamar (Co-Investigator) and other clinical team are required.
e. Law/ rule/ policy/ guidelines (local or international) for referral clinical trial site required.
f. Why NICH is not considered as independent Clinical Trial Site despite of the fact that it is 554 bedded tertiary care children hospital while AKUH has only Peads/children department.

AGENDA ITEM VI:

NATIONAL UNIVERSITY OF MEDICAL SCIENCES, RAWALPINDI REQUEST FOR INCLUSION OF PHASE II AND INSTITUTES IN VACINITY (AFIC, AFIO, AFIRI & AFIMH) IN ALREADY ISSUED LICENCE OF PAK. EMIRATES MILITARY HOSPITAL RAWALPINDI F. No.15-10/2022 DD (PS).

Decision:

The CSC after detailed deliberation decided the case as follows;

a. Pak. Emirates Military Hospital (PEMH) need to submit a fresh application for Phase- II on Form-I along with requisite fee and documents as previously submitted application has already been decided as disposed of.
b. Defer the request to include names of institutes in the vicinity of PEMH (AFIC, AFIO, AFIRI & AFIMH) in already issued CTS license for further deliberation as per provision in the law.

AGENDA ITEM VII:

APPLICATION FOR APPROVAL OF CLINICAL TRIAL TITLED, "ADAPTIVE ASSESSMENT OFTREATMENTS FOR INFLUENZA: A PHASE 2 MULTI-CENTRE

ADAPTIVE RANDOMISED PLATFORM TRIAL TO ASSESS ANTIVIRAL PHARMACODYNAMICS IN EARLY SYMPTOMATIC INFLUENZA INFECTION (AD ASTRA)" AT THE AGA KHAN UNIVERSITY (AKUH), STADIUM ROAD, KARACHI.

Decision:

The CSC deliberated the case and decided to approve the clinical trial titled as, "Adaptive assessment of treatments for influenza: A phase-II multicenter adaptive randomised platform trial to assess antiviral pharmacodynamics in early symptomatic influenza infection (AD Astra)" at the Aga Khan University Hospital (AKUH), Stadium Road, Karachi. The investigational products to be used at AKUH site, with following quantities: -

Favipiravir Strength:(200mg/tab) Frequency: (BD)	Day 1	9+9	18	
	Day 2-4	4+4	32	
		----	50	tablets per patient
			4000	tablets for 80 patients
Oseltamivir Strength: (75mg/Capsules) Frequency: (BD)	Day 1-5	1+1	10	capsule per patient
			800	Capsule for 80 patients

AGENDA ITEM VIII:

REQUEST FOR APPROVAL OF PROTOCOL AMENDMENT VERSION 2 DATE 15 AUGUST 2023 TITLED A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR (BEM) AND RUZASVIR (RZR) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION Approval no F.No.03-47/2023-CT (PS) (46th – CSC) dated 3rd November 2023.

Decision:

The CSC deliberated the case and decided to approve protocol amendment version-2 date 15 August 2023 titled as "A phase-II, open-label study to assess the safety and efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in subjects with chronic hepatitis c virus (HCV) infection."

AGENDA ITEM IX:

HOLDING/STOPPAGE OF CLINICAL TRIAL "A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF BI-26 (STAIN OF BIFIDOBACTERIUM LONGUM, B. INFANTIS) SUPLEMENTATION VS PLACEBO ON WEICHT GAIN ON UNDER WEIGHT INFANTS

Case-I:

Decision: -

The CSC after deliberations decided the case as follows: -

i. *to suspend the clinical trial for further enrollment and also directed to stop further intake of IMPs by already enrolled children. However, follow-up of children will continue.*
ii. *To direct Country-PI and Site PI for following submissions/measures: -*
    a) *Conclusive report for all SAEs in a consolidated way summarizing every SAE individually with IRBs reports and DSMB report along with minutes of meetings.*
    b) *Detailed measures taken regarding management of SAEs / compensation given to subjects.*
    c) *to take special care by the clinical trial sites for enrolled children as decided in 41st meeting of CSC and communicated as per condition 11 of the registration letter CT-0056, viz. "to closely monitor trial subjects and maintain follow-up record to ensure the safety of the trial participants (Infants) and PI will submit trial progress report fortnightly after endorsement from Data Safety & Monitoring Board/Committee".*

iii. *Directed to provide opinion of DSMB regarding letter issued by US-FDA for the risk of invasive disease in association with use of B. infantis strains including Bi-26 in preterm infants.*
iv. *Statistical data regarding administration of IMP and occurrence of SAEs.*
v. *Compensation details to death events.*

Case II: **AMENDMENTS FOR CLINICAL TRIAL "A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATE THE EFFECT OF, Bi-26 (STAIN OF BIFIDOBACTERIUM LONGUM, B. INFANTIS) SUPLEMENTATION VS PLACEBO ON WEIGHT GAIN ON UNDER WEIGHT INFANTS", AL-SHIFA TRUST EYE HOSPITAL, RAWALPINDI. F. No.03-31/2023-DD (PS)**.

Decision: -

The CSC after deliberations decided to defer the amendments in the protocol because the trial has been suspended vide letter No. 03-31/2023-DD-PS dated 08th December 2023.

AGENDA ITEM X:

ADDITION OF TWO NEW CLINICAL TRIAL SITES FOR THE CLINCAL TRIAL TITLED AS "ANTICOAGULATION FOR STROKE PREVENTION WITH RECENT EPICODES OF PERIOPERATIVE ATRIAL FIBRILLATION AFTER NON-CARDIAC SURGERY – THE ASPIRE-AF TRIAL F.03-34/2023-DD (CT)

Decision: -

The CSC after deliberations decided to approve two (02) additional clinical trial sites along with site-PIs, as follows: -

Sr.	*Site(s)*	*CTS*	*PI*	*CNIC*
01	*Aga Khan International Hospital*	*0003*	*Yawer Saeed*	*42101-1861615-3*
02	*Dow University of Health Sciences*	*0068*	*Muhammad Tariq*	*42201-0695908-3*

AGENDA ITEM XI:

WITHDRAWAL OF APPLICATION DUE TO EARLY RECRUITMENT CLOSURE OF TRIAL "DECREASING POSTOPERATIVE BLOOD LOSS BY TOPICAL VS INTRAVENOUS TRANEXAMIC ACID IN OPEN CARDIAC SURGERY (DEPOSITION)" TRIAL. (F. NO.03-21/2022 DD (PS).

Decision: -

The CSC after deliberations acceded to the request of applicant to withdraw the application of subject clinical trial, titled, "Decreasing postoperative blood loss by topical vs intravenous Tranexamic acid in open cardiac surgery (deposition)".

AGENDA ITEM XII:

IRB APPROVAL FOR MAYO HOSPITAL LAHORE FOR INVESTIGATOR BROCHURE VERSION 3.0 DATED MARCH 13, 2023, PROTOCOL AMENDMENT VERSION 4.0 OF JUNE 6, 2023 AND ICF AMENDMENT V3.0 PAK DATED AUGUST 08,2023 FOR TRIAL "A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF THE EFFICAY AND SAFETY OF BCD-201 (JS BIOCAD) AND KEYTRUDA IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (F. NO.03-24/2023 DD (PS).

A. **NOTIFICATION FOR CLOSE OUT OF INACTIVE SITES FOR TRIAL "A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF THE EFFICAY AND**

SAFETY OF BCD-201 (JS BIOCAD) AND KEYTRUDA IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (F. NO.03-24/2023 DD (PS).

DRK (CRO) vide letter dated 15 Nov 2023 has notified that following sites have been closed.

Sr.	Clinical Trial Site	PI	Screened patients	Screen Failure	Randomized / Active Patients	Close Out Date
1.	Shifa International Hospital Islamabad	Dr. Saud Ghazi	0	0	0	04-10-2023
2.	Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore	Dr. Syed Abdullah Javed Bukhari	3	3	0	18-10-2023
3.	Jinnah Hospital Lahore	Dr. Kausar Bano	4	4	0	01-11-2023

B. CHANGE OF COUNTRY PRINICIPAL INVESTIGATOR FOR TRIAL "A RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF THE EFFICAY AND SAFETY OF BCD-201 (JS BIOCAD) AND KEYTRUDA IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (F. NO.03-24/2023 DD (PS).

Decision: -

The CSC after deliberations decided as follows:

a. *to approve the conduction/continuation of clinical trial at Mayo Hospital, Lahore as per following amended documents which were approved by CSC in its 45th CSC meeting held on 13th October 2023*

   i. *Clinical Study Protocol Version 4.0 June 06, 2023.*
   ii. *Investigator's Brochure Version 3.0 of March 15, 2023.*
   iii. *Informed Consent Form (English & Urdu) Version ICF V3.0 PAK dated 08-08-2023.*

b. *acceded to the request for close out of following sites:*

Sr.	*Clinical Trial Site*	*PI*	*Screened patients*	*Screen Failure*	*Randomized / Active Patients*	*Close Out Date*
1.	*Shifa International Hospital Islamabad*	*Dr. Saud Ghazi*	*0*	*0*	*0*	*04-10-2023*
2.	*Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore*	*Dr. Syed Abdullah Javed Bukhari*	*3*	*3*	*0*	*18-10-2023*
3.	*Jinnah Hospital Lahore*	*Dr. Kausar Bano*	*4*	*4*	*0*	*01-11-2023*

c. *The CSC authorized the Chairman CSC to issue approval of Change of Country PI after submission of application by new country PI along with consent/NOC from the trial Sponsor.*

AGENDA ITEM XIII:

CLOSEOUT REPORT QUERY RESPONSE FROM SHIFA INTERNATIONAL HOSPITAL FOR CLINICAL TRIAL "A RANDOMIZED, PHASE-III PLACEBO CONTROLLED TRIAL OF COLCHICINE FOR THE PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY (COP-AF)" CT-0013 / 03-37/2020-DD (PS)

Decision: -

The CSC after deliberations decided to defer Close-out report to further analyze / review of report by members of CSC and it will be placed in forthcoming CSC meeting for deliberations.

AGENDA ITEM XIV:

CLOSEOUT REPORT QUERY RESPONSE FROM SITE OF SHIFA INTERNATIONAL HOSPITAL DATED 10.10.2023 OF THE CLINICAL TRIAL "PERI-OPERATIVE ISCHEMIC EVALUATION-3 (POISE-3) TRIAL. F.NO.03-07/2019-CT(PS)

Decision: -

Defer Close-out report to further analyze / review of report by members of CSC and it will be placed in forthcoming CSC meeting for deliberations.

AGENDA ITEM XV:

ADDITION OF MISSING DOCUMENTS IN AMENDMENTS APPROVAL FOR CLINICAL TRIAL "A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVAUATE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR IN HIGH RISK OUTPATIENTS WITH COVID-19. F.NO.03-37/2023-DD-CT(PS)

Decision: -

CSC after deliberations decided to approve following documents:

i. *AT-03A-017 Statistical Analysis Plan dated 14 Aug 2023_V2.1.*
ii. *AT-03A-017_Doctor Referral Letter_v2_28 Jun2023.*
iii. *AT-03A-017_Key Eligibility Pocket Reference_V2.0_12 Jul 2023.*

AGENDA ITEM XVI:

APPLICATION FOR APPROVAL OF A PHASE-III CLINICAL TRIAL TITLED "A DOUBLE-BLIND, RANDOMIZED CLINICAL STUDY OF THE EFFICACY AND SAFETY OF MONOTHERAPY WITH BCD-254 AND DARZALEX® IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA" FROM SHAHEED ZULFIQAR ALI BHUTTO MEDICAL UNIVERSITY, ISLAMABAD. F. No.03-49/2023-CT (PS).

Decision: -

The CSC after deliberation and discussion decided to defer the case for following points:

a. *Review of the Phase I Clinical Study Report (CSR) of the trial.*
b. *submission of CoPP for Darzalex®.*

AGENDA ITEM XVII:

APPLICATION FOR AMENDMENT IN ALREADY APPROVED CLINICAL TRIAL TITLED "TRANSNASAL CAPSULE ENDOMICROSCOPY FOR VISUALIZATION OF THE SMALL INTESTINE IN ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) POPULATION IN PAKISTAN. F. No.03-18/2020-DD (PS).

Decision: -

The CSC decided to defer the case for further discussion and Provision of GMP Certificate or its equivalent ISO 13485 Certificate for further consideration of the case.

AGENDA ITEM XXVIII: (Amendments, Progress Report & Extension in Trial Duration)

MISCELANNEOUS APPLICATIONS RELATED TO CLINICAL TRIAL TITLED "A RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVT06 COMPARED WITH EU-EYLEA ® IN SUBJECTS WITH NEOVASCULAR (WET) AGE-RELATED MACULAR

DEGENERATION (ALVOEYE)", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-12/2022-CT.

A. Amendments
Decision: -

The CSC after deliberation decided to approve Amendments in already approved of Clinical Trial Titled "A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (Wet) Age related Macular Degeneration (ALVOEYE)" and approved the following amended documents:

- *Protocol V4.0 dated 09-Aug-2023.*
- *Investigators Brochure Ed 5 dated 04-Apr-2023.*

B. Extension in Trial Duration & Progress Report.

Decision: -

The CSC after detailed discussion decided as follows:

a. *to approve extension in trial duration till November 2024, already approved Clinical Trial titled, "A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (Wet) Age related Macular Degeneration (ALVOEYE)".*
b. *To defer the trial progress report for further deliberation and discussion.*

AGENDA ITEM XIX: (Addition of CTS in already approved Clinical Trial)

APPLICATION FOR ADDITION OF CTS FOR AN ALREADY APPROVED CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL PHASE IIB STUDY TO ASSESS EFFICACY AND SAFETY OF HH-003 INJECTION IN SUBJECTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION (HH-003-204)", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-45/2023-CT (PS)

Decision: -

The CSC after detailed deliberation decided to approve the addition of site upon trial principal investigator request and allowed to conduct Clinical Trial titled' "A Multicenter, Randomized, Controlled, Open-Label Phase IIb Study to Assess Efficacy and Safety of HH-003 Injection in Subjects with Chronic Hepatitis Delta Virus Infection (HH-003-204)" at Clinical Trial Site at Clinical Trial Unit, Dr. Ziauddin Hospital, Clifton Campus, Karachi.

AGENDA ITEM XX: (Amendments in documents and increase in 15 subjects)

APPLICATION FOR AMENDMENTS IN DOCUMENTS AND INCREASE IN 15 SUBJECTS IN ALREADY APPROVED CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL PHASE IIB STUDY TO ASSESS EFFICACY AND SAFETY OF HH-003 INJECTION IN SUBJECTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION (HH-003-204)", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-45/2023-CT (PS)

Decision: -

The CSC after deliberation decided as follows:

a. *to approve an increase enrolment (15 additional Subjects) and Amendments in already approved Clinical Trial Titled "A multicenter, randomized, controlled, open-label, phase IIb study to assess efficacy and safety of HH-003 injection in subjects with chronic*

hepatitis delta virus infection (HH003-204)" and approved the following amended documents:

S.No.	Document Name	Version	Date
1	Banner Advertisement (English Urdu & TCert)	V01	09Jun2023
2	Patient Appointment Card (English Urdu & TCert)	V01	21Jun2023
3	Patient Brochure (English Urdu & TCert)	V01	20Jun2023
4	Patient Poster (English Urdu & TCerr)	V01	09Jun2023
5	Patient Study Guide (English Urdu & TCert)	V01	20Jun2023
6	Study Information Slides	V01	20Jun2023
7	Eligibility Criteria Card	V01	20Jun2023
8	Mini Protocol Booklet	V01	21Jun2023
9	Physician Referral Letter	V01	201un2023

b. Further, The Committee also approved the following additional quantities of IMPs and Lab kits required for additional 15 subject's enrolment:

- **IMPs**

IMP Detail:

Name of IP	Quantity of IP required for one (1) patient	Quantity of IP required for 12 patients in treatment group	Total Quantity of IP required (including 25% overage)
HH-003 Injection 300 mg/6ml/vial	**Treatment Group l:** Assuming an avg patient wt is 100kg 20mg/kg X 100kg=2,000mg 300mg: 1 vial 2000mg = 7 vials 7 vials/cycle/patient X 24 cycles: 168 vials/patient **Treatment Group 2:** Assuming an avg patient wt is l00kg l0mg/kg X 100kg: 1,000mg 300mg = I vial 1000mg = 4 via1 4 vials/cycle/patient X 24 cycles =96 vials/patient	Treatment Group 1: 168 vials/patient x 6 patients: 1008 vials Treatment Group 2: 96 vials/patient x 6 patients = 576 vials	1584x125%= 1,980 vials
	Total	**1584 vials**	**1980 vials**

Manufacturer's name and address as per COA and GMP certificate:
Intellective Biologics (Suzhou) Co., Ltd., No. 96, Yinhe Road, Southeast Street, Changshu, Suzhou, Jiangsu, China.

Batch and Expiry:
Batch Number: IP208DPC20230301
Expiry: 2025103112

***Protocol No.**: HH003-204*

Packaging site and address:
Shanghai TaiKun Pharmaceutical Technology Co., Ltd., No. 351, Renqing Rd., Pudong New District, Shanghai, China.

- **Lab Kits**

Lab Kits and Ancillary Details:

a) Lab Kits:

Description	Qty	Description	Qty
Kit A – Screening	78	Kit-M- Treatment Group Drug Resistance	8
Kit B - NrtIs Pre-Treatment	24	Kit-N - Treatment Group Early Term	8
Kit C - Treatment Group V1 W0	16	Kit-O-Treatment Group Unscheduled	8
Kit D - Treatment Group V3 W4	16	Kit-P - Control Group V1 W0	4
Kit E - Treatment Group V5 W8	16	Kit-Q-Control Group V 3N 4N 6N 7 EUZEU3	24
Kit F-Treatment Group Inten PK V7 W12	16	Kit-R - Control Group V8A/10 EOT/FU5	12

Kit G-Treatment Group PK V7 Wl224l48H	*32*	*Kit-S - Control Group V5N9|FU4*	*12*
Kit H - Treatment Group Y9Nll/FU3	*47*	*Kit-T - Control Group Drug Resistance*	*3*
Kit I - Treatment Group Vl3 W24	*16*	*Kit-U-Control Group Term*	*3*
Kit J - Treatment Group V25 EOT/IU5	*32*	*Kit-V - Control Group Unscheduled*	*3*
Kit K - Treatment Group YI9EU4	*32*	*Kit-W - Control Group Unscheduled*	*16*
Kit L - Treatment Group FU2W52	*16*		

AGENDA ITEM XXI: (Amendments)

APPLICATION FOR AMENDMENTS IN ALREADY APPROVED CLINICAL TRIAL TITLED "A PHASE 3, RANDOMIZED, OBSERVER-BLIND, CONTROLLED, MULTICENTER, CLINICAL STUDY TO EVALUATE IMMUNOGENICITY AND SAFETY OF A HIGH-DOSE MF59 ADJUVANTED QUADRIVALENT SUBUNIT CELL-DERIVED INFLUENZA VACCINE (aQIVc HD) IN COMPARISON WITH A NON-ADJUVANTED QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (QIVr) AND AN MF59-ADJUVANTED QUADRIVALENT SUBUNIT EGG-DERIVED INFLUENZA VACCINE (aQIV), IN ADULTS AGED 50 YEARS AND OLDER", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-46/2023-CT (PS)

Decision: -

The CSC after deliberation decided to approve Amendments in already approved of Clinical Trial Titled "A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59 Adjuvanted Quadrivalent Subunit Cell-Derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-Adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVc) and An MF59-Adjuvanted Quadrivalent Subunit Egg-Derived Influenza Vaccine (aQIV), in Adults Aged 50 Years And Older" and approved the following amended documents:

S.No.	***Document Name***	***Version***	***Date***
1	*V201-03_PAK Main ICF (English, Urdu & TVF)*	*V2.0PAKV2.0*	*03Oct2023*
2	*V201-03_Patient Poster (English, Urdu & TVF)*	*V01*	*09Oct2023*
3	*V201-03 Lab Manual*	*V01*	*29Aug2023*
4	*V201 -03 Investigator Pharmacy Manual*	*V2.0*	*08Aug2023*

AGENDA ITEM XXII:

A. Amendments)

APPLICATION/NOTIFICATION FOR NON-SUBSTANTIAL AMENDMENT FOR APPROVAL OF CLINICAL TRIAL TITLED "A PHASE-III, MULTICENTRE. RANDOMIZED, DOUBLE-BLIND, 24-WEEK STUDY OF THE CLINICAL AND ANTIVIRAL EFFECT OF S-217622 COMPARED WITH PLACEBO IN NON-HOSPITALIZED PARTICIPANTS WITH COVID-19", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-25/2023-CT (PS)

Decision: -

The CSC after deliberation decided to approve Amendments in already approved of Clinical Trial Titled "A Phase-III, Multi-Centre. Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared with Placebo in Non-Hospitalized Participants with COVID-19" and approved the following amended documents:

- *Amended Protocol (Version 6.0) dated 25 October 2023*
- *Amended Investigator's Brochure (Edition 6.0) dated 11 July 2023*
- *Informed Consent Form V7.1_Pak V1.0, dated 20 October 2023.*

B. PROGRESS REPORT AND GLOBAL SUSAR REPORT.

Decision: -

The CSC after deliberation decided to defer the case for further deliberation and discussion on Progress Report and Global SUSAR Report for Clinical Trial Titled "A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19".

AGENDA ITEM XXIII: (Progress Reports and Trial Duration Extension)

PROGRESS REPORTS AND APPLICATION FOR EXTENSION IN TRIAL DURATION IN ALREADY APPROVED CLINICAL TRIAL TITLED, "SCY-078-305, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SCY-078-305 (IBREXAFUNGERP) IN PATIENTS WITH FUNGAL DISEASES THAT ARE REFRACTORY TO OR INTOLERANT OF STANDARD ANTIFUNGAL TREATMENT (FURI)". F.NO.03-61/2021-CT

Decision: -

The CSC after deliberation and discussion decided the case as follows:

a. *to grant one-year extension in trial duration (w.e.f. 18th October 2023) for already approved Clinical Trial Titled "SCY-078-305, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SCY-078-305 (Ibrexafungerp) in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)".*
b. *To defer the progress report for further deliberation and discussion.*

AGENDA ITEM XXIV: Trial Duration Extension

APPLICATION FOR EXTENSION IN TRIAL DURATION IN AN ALREADY APPROVED CLINICAL TRIAL TITLED, "SCY-078-305, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SCY 078 (IBREXAFUNGERP) IN PATIENTS WITH CANDIDIASIS INCLUDING CANDIDEMIA, CAUSED BY CANDIDA AURIS". (CARES) F.No.03-15/2021-CT.

Decision: -

The CSC after deliberation, decided to grant one-year extension in trial duration (w.e.f. 19th October 2023*) for already approved Clinical Trial Titled "SCY-078-305, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SCY 078 (IBREXAFUNGERP) In Patients with Candidiasis Including Candidemia, Caused by Candida Auris (CARES)".*

AGENDA ITEM XXV:

APPLICATION FOR IMPORT OF ADDITIONAL QUANTITIES OF IMPs FOR ALREADY APPROVED PHASE-IV CLINICAL TRIAL TITLED, "RANDOMIZED, OPEN LABEL, MULTICENTER, NON-INFERIORITY CLINICAL TRIAL FOR NEW TREATMENT MODALITIES FOR CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA TROPICA". F. No.03-60/2021-DD (PS).

Decision: -

The CSC after deliberation decided to approve following additional IMPs quantities and Medical Device (Thermo Med 1.8) to be imported after getting import licence from respective DRAP field office:

Study arm (monotherapy MF or combination MF+TT)	*Number of remaining participants*	*Required Miltefosine 50mg caps per participant*	*Total required miltefosine caps 50mg*	*Number of boxes miltefosine required (SUD)*	*Number of boxes to order*	*Number of capsules to order*
Miltefosine monotherapy arm	*108*	*84*	*9,072*	*162*	*163*	*9,128*
Miltefosine+ Thermotherapy arm	*108*	*63*	*6,804*	*122*	*123*	*6,888*
Total		***147***	***15,876***	***284***	***286***	***16016***
The Committee also allowed to import 02 thermotherapy machine, the Thermo Med 1.8 to be used at newly approved CTS by the CSC.						

AGENDA ITEM XXVI: (RATIFICATION OF TYPO ERROR)

APPLICATION FOR EXTENSION IN TRIAL DURATION AND AMENDMENT IN PROTOCOL AND RELATED DOCUMENTS OF ALREADY APPROVED PHASE-IV CLINICAL TRIAL TITLED, "RANDOMIZED, OPEN LABEL, MULTICENTER, NON-INFERIORITY CLINICAL TRIAL FOR NEW TREATMENT MODALITIES FOR CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA TROPICA". F. No.03-60/2021-DD (PS).

Decision: -

The Committee ratified the letter issued on 20th November 2023.

AGENDA ITEM XXVII:

CLOSE-OUT REPORT OF CLINICAL TRIAL TITLED, "PREVENTION OF METRNAL & NEONATAL DEATH / INFECTIONS WITH A SINGLE ORAL DOSE OF AZITHROMYCIN IN WOMEN IN LABOR (IN LOW & MIDDLE INCOME COUNTRIES), A RANDOMIZED CONTROLLED TRIAL. (A-PLUS) F. No.03-09/2019-DD (PS).

Decision: -

The CSC after deliberation decided the case as follows:

a. *to defer the case for further deliberation and discussion on Close-Out Report for Clinical Trial Titled "Prevention of Maternal & Neonatal Death / Infections with A Single Oral Dose of Azithromycin in Women in Labor (In Low- & Middle-Income Countries), A Randomized Controlled Trial. (A-PLUS)".*
b. *to direct PI for submission of detailed progress report of the trial.*

AGENDA ITEM XXVIII: (Detailed Progress Report)

DETAILED PROGRESS REPORT & END OF TREATMENT NOTIFICATION FOR CLINICAL TRIAL TITLED "A PHASE-III, RANDOMIZED, OBSERVER-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF SEQIRUS-CELL-BASED QUADRIVALENT SUBUNIT INFLUENZA VIRUS VACCINE (QIVc) COMPARED TO A NON-INFLUENZA VACCINE WHEN ADMINISTERED IN HEALTHY SUBJECTS AGED 6 MONTHS THROUGH 47 MONTHS", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-11/2022-CT (PS)

Decision: -

The CSC after deliberation decided to defer the case for further deliberation and discussion on Progress Report for Clinical Trial Titled "A Phase-III, Randomized, Observer-Blind,

Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of SEQIRUS-Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to A Non-Influenza Vaccine When Administered in Healthy Subjects Aged 6 Months Through 47 Months".

CASE-II: (END of Treatment Notification)

DETAILED PROGRESS REPORT & END OF TREATMENT NOTIFICATION FOR CLINICAL TRIAL TITLED "A PHASE-III, RANDOMIZED, OBSERVER-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF SEQIRUS-CELL-BASED QUADRIVALENT SUBUNIT INFLUENZA VIRUS VACCINE (QIVc) COMPARED TO A NON-INFLUENZA VACCINE WHEN ADMINISTERED IN HEALTHY SUBJECTS AGED 6 MONTHS THROUGH 47 MONTHS", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-11/2022-CT (PS)

Decision: -

The CSC decided to defer the case for further deliberation upon completion of Treatment Notification for Clinical Trial Titled "A Phase-III, Randomized, Observer-Blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of SEQIRUS-Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to A Non-Influenza Vaccine When Administered in Healthy Subjects Aged 6 Months Through 47 Months".

AGENDA ITEM XXIX: CLINICAL STUDY REPORT

CLINICAL STUDY REPORT OF CLINICAL TRIAL TITLED "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFICACY & SAFETY OF CBP-307 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (UC)" F.NO.03-59/2021 DD (PS).

Decision: -

The CSC decided to defer the case for further deliberation on Clinical Study Report (CSR) of Clinical Trial Titled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase-II Clinical Trial to Evaluate the Efficacy & Safety of CBP-307 in Subjects with Moderate to Severe Ulcerative Colitis (UC)".

AGENDA ITEM XXX: SAEs AND STUDY PROGRESS REPORTS

SAEs AND STUDY PROGRESS REPORTS OF CLINICAL TRIAL TITLED "EFFECTIVENESS OF NOVEL APPROACHES TO RADICAL CURE WITH TAFENOQUINE AND PRIMAQUINE (EFFORT)- A RANDOMIZED CONTROLLED TRIAL IN P. VIVAX PATIENTS". FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-10/2022-DD (PS)

Decision: -

The CSC decided to defer the case for further deliberation on SAEs, Study Progress and DSMB report of Clinical Trial Titled "Effectiveness of Novel Approaches to Radical Cure with Tafenoquine and Primaquine (EFFORT)- A Randomized Controlled Trial in P. VIVAX Patients".

AGENDA ITEM XXXI: Update for 1st DSMB for Pakistan

UPDATE FOR 1ST DSMB FOR PAKISTAN OF CLINICAL TRIAL TITLED "A MULTI-COUNTRY, MULTI-CENTER, OPEN-LABELLED, RANDOMIZED, CONTROLLED, EXTENDED PHASE III CLINICAL TRIAL TO EVALUATE THE IMMUNOGENICITY AND TOLERABILITY OF SABIN STRAIN INACTIVATED POLIOVIRUS VACCINE

ADMINISTERED WITH OR WITHOUT ROUTINE INFANT VACCINES", FROM AGA KHAN UNIVERSITY HOSPITAL, KARACHI. F. No.03-40/2023-CT (PS).

Decision: -

The CSC decided as follows:

a. *To defer the case for further deliberation on DSMB for Pakistan of Clinical Trial Titled "A Multi-Country, Multi-Center, Open-Labelled, Randomized, Controlled, Extended Phase III Clinical Trial to Evaluate the Immunogenicity and Tolerability of Sabin Strain Inactivated Poliovirus Vaccine Administered with or Without Routine Infant Vaccines.*
b. *To direct Country PI and Site PI to comply following directions:*
    i. *Remain in close contact with all trial participants/subjects*
    ii. *Take all necessary measures/actions to ensure the safety of the participants/subjects*
    iii. *Provide necessary medical treatment, if required.*

AGENDA ITEM XXXII:

DSUR AND CLINICAL STUDY REPORT (CSR) OF FOR CLINICAL TRIAL TITLED "A MULTICENTER, SEAMLESS, RANDOMIZED, THIRD-PARTY-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY & EFFICACY OF MEPLAZUMAB (INJECTION) IN ADDITION TO STANDARD CARE FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS" F.NO.03-54/2021 DD (PS).

Decision: -

The CSC decided to defer the case for further deliberation on Clinical Study Report (CSR) of for clinical trial titled "A Multicenter, Seamless, Randomized, Third-Party-Blind Clinical Trial to Evaluate the Safety & Efficacy of Meplazumab (Injection) In Addition to Standard Care for The Treatment of Covid-19 In Hospitalized Adults.

AGENDA ITEM XXXIII:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF PERISPA (EPERISONE) 50 MG TABLETS MANUFACTURED BY M/S PLATINUM PHARMACEUTICALS (PVT) LIMITED, KARACHI. COMPARED WITH MYONAL (EPERISONE) 50MG TABLETS MANUFACTURED BY M/S EISAI Co. LTD., JAPAN. F. No. 14-02/2022 DD (PS)

Decision: -

The CSC after detailed deliberation, decided the case as follows:

a. *to approve the BA/BE Study titled, "Bioequivalence Study of Perispa (Eperisone HCI) Tablet 50mg, a single-dose, randomized, open-label, two-period, two-sequence, two treatments, 2 x 2, crossover bioequivalence study of Perispa (Eperisone HCL) Tablet 50mg compared with Myonal (Eperisone HCL) Tablet 50mg in 34 healthy adult human subjects, under fasting condition." to be conducted at IBBPS-DUHS, Ojha Campus, SUPARCO Road, Karachi.*
b. *PI will provide details of reference product regarding Import license, mode of purchase, shipment details for record.*

AGENDA ITEM XXXIV:

BIO EQUIVALENCE STUDY OF EMPA-Q 25MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.

Decision: -

The CSC after deliberation and discussion, acceded to the request for withdrawal of application by applicant for BA/BE Study project titled, "A balanced, open labeled, randomized, analyst blind, single center, two-period, two sequence, crossover design single dose oral bioequivalence study of Empa-Q Tablet (each tablet contains Empagliflozin 25 mg) of Wilshire Laboratories (Pvt.) Ltd. With Jardiance Tablet (each tablet contains empagliflozin 25mg) of Boehringer Ingelheim (USA) in 24+2 (Standby) normal, healthy, adult, male, human subject under fasting conditions." of M/s Olive Worldwide (SMC-PVT.) Ltd, Lahore.

AGENDA ITEM XXXV:

BIO EQUIVALENCE STUDY OF QAZZO 20MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.

Decision: -

The CSC after deliberation and discussion, acceded to the request for withdrawal of application by applicant for BA/BE Study project titled, "A balanced, open labeled, randomized, analyst blind, single center, two treatments, two-period, two sequence, crossover design single dose oral bioequivalence study of Qazzo Tablet (each tablet contains Rosuvastatin Calcium 20 mg) of Wilshire Laboratories (Pvt.) Ltd. With Crestor Tablet (each tablet contains Rosuvastatin Calcium 20mg) of AstraZeneca (Canada) in 24 normal, healthy, adult, male, human subject under fasting conditions." of M/s Olive Worldwide (SMC-PVT.) Ltd, Lahore.

AGENDA ITEM XXXVI:

BIO EQUIVALENCE STUDY OF RIVA Q 20MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.

Decision: -

The CSC after deliberation and discussion, acceded to the request for withdrawal of application by applicant for BA/BE Study project titled, "A balanced, open label, randomized, analyst-blind, single center, two-treatment, two-period, two-sequence, crossover design single dose oral bioequivalence study of Riva Q Tablet (Each Tablet contains Rivaroxaban 20 mg) of Wilshire Laboratories (Pvt) Ltd. with Xarelto Tablet (Each Tablet contains Rivaroxaban 20 mg) of Bayer (Canada) in 28 normal, healthy, adult, male, human subjects under fasting conditions." of M/s Olive Worldwide (SMC-PVT.) Ltd, Lahore.

AGENDA ITEM XXXVII:

BIO EQUIVALENCE STUDY OF ZUNE 40MG TABLET BY M/S OLIVE WORLDWIDE (SMC-PVT.) LTD.

Decision: -

The CSC after deliberation and discussion, acceded to the request for withdrawal of application by applicant for BA/BE Study project titled, "A balanced, open label, randomized, analyst-blind, single center, two-treatment, two-period, two-sequence,

crossover design single dose oral bioequivalence study of Zune Tablet (Each Tablet contains Esomeprazole Magnesium 40 mg) of Wilshire Laboratories (Pvt.) Ltd. With Nexium Tablet (Each Tablet contains Esomeprazole Magnesium 40 mg) of AstraZeneca (Canada) in 24 normal, healthy, adult, male, human subjects under fasting conditions." of M/s Olive Worldwide (SMC-PVT.) Ltd, Lahore.

AGENDA ITEM XXXVIII:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF AZITMA® (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH ZITHROMAX® (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S PFIZER PAKISTAN. F. No. 14-06/2020 DD (PS).

Decision: -

The CSC after deliberation and discussion, acceded to the withdrawal of application as per applicant request for BA/BE Study project titled, "BIOEQUIVALENCE STUDY OF AZITMA® (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH ZITHROMAX® (AZITHROMYCIN DIHYDRATE) 500MG TABLET OF M/S PFIZER PAKISTAN.", of CBSCR, ICCBS, University of Karachi, Karachi.

AGENDA ITEM XXXIX:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF DELANZO™DR 60MG (DEXLANSOPRAOLE) CAPSULE OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH DEXILANT® 60MG (DEXLANSOPRAOLE) CAPSULE. F. No. 14-02/2020 DD (PS)

Decision: -

The CSC after deliberation and discussion, acceded to the withdrawal of application as per applicant request for BA/BE Study project titled, "BIOEQUIVALENCE STUDY OF DELANZO™DR 60MG (DEXLANSOPRAOLE) CAPSULE OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH DEXILANT® 60MG (DEXLANSOPRAOLE) CAPSULE.", of CBSCR, ICCBS, University of Karachi, Karachi.

AGENDA ITEM XXXX:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF MOFEST® (MOXIFLOXACIN) 400MG TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH AVELOX® (MOXIFLOXACIN) 500MG TABLET OF M/S BAYER PAKISTAN. F. No. 14-04/2020 DD (PS).

Decision: -

The CSC after deliberation and discussion, acceded to the withdrawal of application as per applicant request for BA/BE Study project titled, "BIOEQUIVALENCE STUDY OF MOFEST® (MOXIFLOXACIN) 400MG TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH AVELOX® (MOXIFLOXACIN) 500MG TABLET OF M/S BAYER PAKISTAN", of CBSCR, ICCBS, University of Karachi, Karachi.

AGENDA ITEM XXXXI:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF OCVIR™ 400/100MG (SOFOSBUVIR/VELPATASVIR) TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH EPCLUSA® 400/100MG (SOFOSBUVIR/VELPATASVIR) TABLET OF M/S GILEAD SCIENCES LTD. F. No. 14-03/2020 DD (PS)

Decision: -

The CSC after deliberation and discussion, acceded to the withdrawal of application as per applicant request for BA/BE Study project titled, "BIOEQUIVALENCE STUDY OF OCVIR™ 400/100MG (SOFOSBUVIR/VELPATASVIR) TABLET OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH EPCLUSA® 400/100MG (SOFOSBUVIR/VELPATASVIR) TABLET OF M/S GILEAD SCIENCES LTD.", of CBSCR, ICCBS, University of Karachi, Karachi.

AGENDA ITEM XXXXII:

REQUEST FOR APPROVAL AND REGISTRATION OF BIOEQUIVALENCE STUDY OF NOVIDATE® (CIPROFLOXACIN) 250MG/5ML SUSPENSION OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH CIPROXIN® 250MG/5ML SUSPENSION OF BAYER PAKISTAN. F. No. 14-05/2020 DD (PS).

Decision: -

The CSC after deliberation and discussion, acceded to the request for withdrawal of application by applicant for BA/BE Study project titled, "BIOEQUIVALENCE STUDY OF NOVIDATE® (CIPROFLOXACIN) 250MG/5ML SUSPENSION OF M/S SAMI PHARMACEUTICALS (PVT) LTD WITH CIPROXIN® 250MG/5ML SUSPENSION OF BAYER PAKISTAN", of CBSCR, ICCBS, University of Karachi, Karachi.

AGENDA ITEM XXXXIII:

APPLICATION FOR LICENSE TO ACT AS CLINICAL TRIAL SITE FOR PHASE-III FROM DEPARTMENTS OF OBSTETRICS AND GYNAECOLOGY (GYNAE WARD 08, 09), JINNAH POST GRADUATE MEDICAL CENTER, KARACHI. F. No.15-54/2023 DD (PS)

Decision:

The CSC after detailed discussion and deliberation decided to authorize the Chairman CSC for issuance of study specific licence (Gynae Ward 08, Jinnah Postgraduate Medical Center, Karachi) after fulfillment of following queries and verification by any of the two panel members:

i. Arrangement for randomization at JPMC.
ii. Applicant/Site PI will make arrangements for IMPs storage at CTU of JPMC
iii. All trial related activities will be carried out at CTU-JPMC.

< The Meeting ended with vote of thanks to and from the Chair.>